238 related articles for article (PubMed ID: 32142966)
1. The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome.
Butterfield J; Weiler CR
J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2533-2541. PubMed ID: 32142966
[TBL] [Abstract][Full Text] [Related]
2. Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation Syndrome.
Butterfield JH
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2542-2546. PubMed ID: 36863614
[TBL] [Abstract][Full Text] [Related]
3. Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation.
Butterfield JH
Int Arch Allergy Immunol; 2020; 181(1):43-50. PubMed ID: 31722348
[TBL] [Abstract][Full Text] [Related]
4. Assessment of in vivo mast cell reactivity in patients with systemic mastocytosis.
Gülen T; Möller Westerberg C; Lyberg K; Ekoff M; Kolmert J; Bood J; Öhd J; James A; Dahlén SE; Nilsson G; Dahlén B
Clin Exp Allergy; 2017 Jul; 47(7):909-917. PubMed ID: 28258965
[TBL] [Abstract][Full Text] [Related]
5. Mast Cell Mediators of Significance in Clinical Practice in Mastocytosis.
Butterfield JH; Ravi A; Pongdee T
Immunol Allergy Clin North Am; 2018 Aug; 38(3):397-410. PubMed ID: 30007459
[TBL] [Abstract][Full Text] [Related]
6. Nontryptase Urinary and Hematologic Biomarkers of Mast Cell Expansion and Mast Cell Activation: Status 2022.
Butterfield JH
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1974-1984. PubMed ID: 35346887
[TBL] [Abstract][Full Text] [Related]
7. Divergent PGD
Butterfield JH; Singh RJ
Prostaglandins Other Lipid Mediat; 2021 Aug; 155():106563. PubMed ID: 34029712
[TBL] [Abstract][Full Text] [Related]
8. Differential mast cell mediators in systemic mastocytosis and hereditary α-tryptasemia.
Giannetti MP; Godwin G; Weller E; Butterfield JH; Castells M
J Allergy Clin Immunol; 2022 Nov; 150(5):1225-1227. PubMed ID: 35550148
[TBL] [Abstract][Full Text] [Related]
9. Increased leukotriene E4 excretion in systemic mastocytosis.
Butterfield JH
Prostaglandins Other Lipid Mediat; 2010 Jun; 92(1-4):73-6. PubMed ID: 20380889
[TBL] [Abstract][Full Text] [Related]
10. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.
Castells M; Butterfield J
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1097-1106. PubMed ID: 30961835
[TBL] [Abstract][Full Text] [Related]
11. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production.
Butterfield JH; Weiler CR
Int Arch Allergy Immunol; 2008; 147(4):338-43. PubMed ID: 18622141
[TBL] [Abstract][Full Text] [Related]
12. Urinary 11β-PGF2α and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders.
Divekar R; Butterfield J
Allergy; 2015 Oct; 70(10):1230-8. PubMed ID: 26095439
[TBL] [Abstract][Full Text] [Related]
13. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
Ravi A; Butterfield J; Weiler CR
J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
[TBL] [Abstract][Full Text] [Related]
14. Analytical and clinical validation of an LC-MS/MS method for urine leukotriene E4: A marker of systemic mastocytosis.
Lueke AJ; Meeusen JW; Donato LJ; Gray AV; Butterfield JH; Saenger AK
Clin Biochem; 2016 Sep; 49(13-14):979-82. PubMed ID: 26908217
[TBL] [Abstract][Full Text] [Related]
15. On the role of PGD2 metabolites as markers of mast cell activation in asthma.
O'Sullivan S
Acta Physiol Scand Suppl; 1999 Apr; 644():1-74. PubMed ID: 10352758
[TBL] [Abstract][Full Text] [Related]
16. Mast Cell Activation Syndrome.
Frieri M
Clin Rev Allergy Immunol; 2018 Jun; 54(3):353-365. PubMed ID: 25944644
[TBL] [Abstract][Full Text] [Related]
17. Urine Mast Cell Mediators in the Evaluation and Diagnosis of Mast Cell Activation Syndrome.
Voelker D; Pongdee T
Curr Allergy Asthma Rep; 2024 Feb; 24(2):33-38. PubMed ID: 38236528
[TBL] [Abstract][Full Text] [Related]
18. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
19. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
[TBL] [Abstract][Full Text] [Related]
20. Transglutaminase 2 expressed in mast cells recruited into skin or bone marrow induces the development of pediatric mastocytosis.
Ahn YM; Hong GU; Kim SH; Lee HJ; Baek HS; Kim MN; Park KY; Ro JY
Pediatr Allergy Immunol; 2015 Aug; 26(5):438-45. PubMed ID: 25952500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
